Clinical Spotlight Series: Hypertriglyceridemia & CV Health-7. Panel Discussion With Audience Questions and Answers

7. Panel Discussion With Audience Questions and Answers

Video Transcription

Video Summary

Panelists discussed GLP‑1 use in severe hypertriglyceridemia, noting real‑world data suggesting no major pancreatitis increase and possibly fewer events; guidelines don’t list hypertriglyceridemia as a contraindication, though caution is advised in patients with prior pancreatitis. They debated triglycerides as a cardiovascular risk factor: TGs are viewed more as a biomarker of insulin resistance/remnant particles than a direct LDL‑like causal factor, and benefits in REDUCE‑IT may reflect pleiotropic effects. For patients on fenofibrate with TG ~200, speakers often stop it if used for CV prevention (no proven benefit on-label), prioritizing statins/LDL lowering; fibrates remain reasonable when TG >500 to prevent pancreatitis. Pill burden and combination therapies were raised; triple “polypills” aren’t common, but emerging agents (e.g., olezarsen) may add benefit, with potential synergy with fibrates.

Keywords

GLP-1

hypertriglyceridemia

pancreatitis

triglycerides

fenofibrate